Sára Ferková

Mrs. Sára Ferková

Department of Pharmacology and Physiology, Université de Sherbrooke, Sherbrooke, Quebec, Canada
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
BFBryan J. Fraser
Bryan J. Fraser
RWRyan P. Wilson
Ryan P. Wilson
SFSára Ferková
Sára Ferková
OIOlzhas Ilyassov
Olzhas Ilyassov
JLJackie Lac
Jackie Lac
CACheryl H. Arrowsmith
Cheryl H. Arrowsmith
Transmembrane Protease, Serine-2 (TMPRSS2) and TMPRSS11D are human proteases that enable SARS-CoV-2 and Influenza A/B virus infections, but their biochemical mechanisms for facilitating viral cell entry remain unclear. We show these proteases spontaneously and efficiently cleave their own zymogen activation motifs, activating their broader protease activity on cellular substrates. We determine TMPRSS11D co-crystal structures with a native and an engineered activation motif, revealing insights into its autocleavage activation and distinct substrate binding cleft features. Leveraging this structural data, we develop nanomolar potency peptidomimetic inhibitors of TMPRSS11D and TMPRSS2. We show that a broad serine protease inhibitor that underwent clinical trials for TMPRSS2-targeted COVID-19 therapy, nafamostat mesylate, was rapidly cleaved by TMPRSS11D and converted to low activity derivatives. In this work, we develop mechanistic insights into human protease viral tropism and highlight both the strengths and limitations of existing human serine protease inhibitors, informing future drug discovery efforts targeting these proteases.

14 October 2024 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
MDMichael Desgagné
Michael Desgagné
MCMagali Chartier
Magali Chartier
CLCamille Lagard
Camille Lagard
SFSára Ferková
Sára Ferková
MCMathieu Choquette
Mathieu Choquette
PSPhilippe Sarret
Philippe Sarret
The opioid crisis has highlighted the urgent need to develop non‐opioid alternatives for managing pain, with an effective, safe, and non‐addictive pharmacotherapeutic profile. Using an extensive structure–activity relationship approach, here we have identified a new series of highly selective neurotensin receptor type 2 (NTS2) macrocyclic compounds that exert potent, opioid‐independent analgesia in various experimental pain models. To our knowledge, the constrained macrocycle in which the Ile12 residue of NT(7–12) was substituted by cyclopentylalanine, Pro7 and Pro10 were replaced by allyl‐glycine followed by side‐chain to side‐chain cyclization is the most selective analog targeting NTS2 identified to date (Ki 2.9 nM), showing 30,000‐fold selectivity over NTS1. Of particular importance, this macrocyclic analog is also able to potentiate the analgesic effects of morphine in a dose‐ and time‐dependent manner. Exerting complementary analgesic actions via distinct mechanisms of nociceptive transmission, NTS2‐selective macrocycles can therefore be exploited as opioid‐free analgesics or as opioid‐sparing therapeutics, offering superior pain relief with reduced adverse effects to pain patients.

19 July 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
MDMichael Desgagné
Michael Desgagné
ADAntoine Désilets
Antoine Désilets
SFSára Ferková
Sára Ferková
MLMatthieu Lepage
Matthieu Lepage
OPOlivier Perreault
Olivier Perreault
PBPierre-Luc Boudreault
Pierre-Luc Boudreault
TMPRSS6 is a potential therapeutic target for the treatment of iron overload due to its role in regulating levels of hepcidin. Although potent TMPRSS6 inhibitors have been previously developed, their lack of specificity requires optimization to avoid potential side effects before pursuing preclinical development with in vivo models. Here, using computer-aided drug design based on a TMPRSS6 homology model, we reveal that the S2 position of TMPRSS6 offers a potential avenue to achieve selectivity against other members of the TTSP family. Accordingly, we synthesized novel peptidomimetic molecules containing lipophilic amino acids at the P2 position to exploit this unexplored pocket. This enabled us to identify TMPRSS6-selective small molecules with low nanomolar affinity. Finally, pharmacokinetic parameters were determined, and a compound was found to be potent in cellulo toward its primary target while retaining TTSP-subtype selectivity and showing no signs of alteration in in vitro TEER experiments.

30 March 2025 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SFSára Ferková
Sára Ferková
MLMatthieu Lepage
Matthieu Lepage
ADAntoine Désilets
Antoine Désilets
KAKevin Assouvie
Kevin Assouvie
GLGabriel Lemieux
Gabriel Lemieux
PBPierre-Luc Boudreault
Pierre-Luc Boudreault

Verified
Journal Article
Open access
PDF file
SFSára Ferková
Sára Ferková
UFUlrike Froehlich
Ulrike Froehlich
MNMarie-Edith Nepveu-Traversy
Marie-Edith Nepveu-Traversy
AMAlexandre Murza
Alexandre Murza
TATaha Azad
Taha Azad
PBPierre-Luc Boudreault
Pierre-Luc Boudreault
Medicinal chemistry is constantly searching for new approaches to develop more effective and targeted therapeutic molecules. The design of peptidomimetics is a promising emerging strategy that is aimed at developing peptides that mimic or modulate the biological activity of proteins. Among these, stapled peptides stand out for their unique ability to stabilize highly frequent helical motifs, but they have failed to be systematically reported. Here, we exploit chemically diverse helix-inducing i, i + 4 constraints—lactam, hydrocarbon, triazole, double triazole and thioether—on two distinct short sequences derived from the N-terminal peptidase domain of hACE2 upon structural characterization and in silico alanine scan. Our overall objective was to provide a sequence-independent comparison of α-helix-inducing staples using circular dichroism (CD) and nuclear magnetic resonance (NMR) spectroscopy. We identified a 9-mer lactam stapled peptide derived from the hACE2 sequence (His34-Gln42) capable of reaching its maximal helicity of 55% with antiviral activity in bioreporter- and pseudovirus-based inhibition assays. To the best of our knowledge, this study is the first comprehensive investigation comparing several cyclization methods with the goal of generating stapled peptides and correlating their secondary structures with PPI inhibitions using a highly topical model system (i.e., the interaction of SARS-CoV-2 Spike RBD with hACE2).

22 October 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
ALAnnik Lanoie
Annik Lanoie
SFSára Ferková
Sára Ferková
ÉCÉdouard Caron-Duval
Édouard Caron-Duval
JDJuliana C.C. Dallagnol
Juliana C.C. Dallagnol
SDSitan Diarra
Sitan Diarra
PSPhilippe Sarret
Philippe Sarret
Contulakins are a subclass of conopeptides derived from cone snail venom, known for their analgesic properties mediated through activation of neurotensin receptors NTS1 and NTS2. Among them, contulakin-G, isolated from Conus geographus, exhibits a favorable pharmacokinetic profile, including a 24-hour plasma half-life, and produces potent opioid-independent antinociceptive effects. To facilitate synthesis while preserving analgesic efficacy, we investigated the structure-activity relationships of contulakin-G, focusing on modifications to the glycosylated Thr10 residue. In the first series, Thr10 was substituted by natural and non-natural amino acids encompassing diverse physiochemical and steric properties. Most substitutions had minimal impact on receptor affinity, though some increased the NTS2/NTS1 selectivity ratio. Of these, only the Tyr10 analog retained antinociceptive efficacy comparable to native contulakin-G. Building on tyrosine's hydrophobicity, a second series introduced non-natural hydrophobic residues at position 10, including Gln-cycloheptyl, Gln-biphenylmethyl, and Gln-dimethyladamantyl, along with a non-glycosylated form. In both tonic and postoperative pain models, the non-glycosylated and Gln-cycloheptyl analogs demonstrated potent analgesic activity, comparable to contulakin-G and reversed mechanical allodynia in a neuropathic pain model. In contrast, a third series involving N-terminal truncations led to reduced plasma half-life and loss of antinociceptive efficacy, underscoring the importance of the N-terminal region. Molecular modeling further revealed that full-length analogs engage a broader NTS2 binding interface than truncated derivatives. These findings support the development of synthetically accessible contulakin-G analogs as promising non-opioid analgesics.